Imatinib (Gleevec), a small-molecule inhibitor of the oncogenic fusion kinase BCR-ABL, was first approved by the FDA in 2001 for the treatment of chronic myeloid leukemia (CML) [7]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.